Nurix Therapeutics (NRIX) news
Recent news
Nurix Therapeutics Q3 revenue USD 673.064 million
Nurix Therapeutics reported third-quarter revenue of $673.064 million, reflecting continued growth in its targeted protein degradation platform and strategic collaborations. The company has been advancing its pipeline through partnerships with major pharmaceutical firms, including Roche, Gilead…
AInvest Wire · 11h agoNurix 3Q R&D expenses $79.3M, est. $77.1M
Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported research and development (R&D) expenses of $79.3 million for the third quarter of fiscal 2024, exceeding the estimated $77.1 million for the period. The increase in R&D spending reflects the company’s continued investment in its clinical trial…
AInvest Wire · 11h agoNurix 3Q rev. $19.9M est. $24.4M
Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported financial results for the first quarter of fiscal 2026, with revenue coming in below estimates. Revenue for the three months ended February 28, 2026, was $6.3 million, compared to $18.5 million in the same period in 2025. This decline was primarily…
AInvest Wire · 11h agoNurix Therapeutics Q3 EPS USD 4.73
AInvest Wire · 11h agoNurix Therapeutics Q3 net income USD 549.807 million
Nurix Therapeutics reported a net income of USD 549.807 million for the third quarter of 2026, reflecting strong financial performance during the period. The company’s results highlight its continued progress in the biotechnology sector, particularly in the development of genetic medicines for…
AInvest Wire · 11h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.